Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.85 |
| ▸ | HTR2A | P28223 | 11/20 | 0.76 |
| ▸ | HRH1 | P35367 | 6/20 | 0.71 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL12471692 | 0.99 | HTR2C (0.84) | HTR2CHTR2AHRH1HRH4 | |
| SCHEMBL10194082 | 0.93 | HTR2A (0.87) | HTR2CHTR2AHRH1 | |
| SCHEMBL10194034 | 0.92 | HTR2A (0.76) | HTR2CHTR2AHRH1 | |
| SCHEMBL23242509 | 0.92 | HTR2C (1.00) | HTR2CHTR2AHRH1 | |
| SCHEMBL10194142 | 0.90 | HTR2A (0.89) | HTR2CHTR2AHRH1 | |
| SCHEMBL10194056 | 0.90 | HTR2C (0.88) | HTR2CHTR2AHRH1 | |
| SCHEMBL10194066 | 0.90 | HTR2C (0.76) | HTR2CHTR2AHRH1HRH4 | |
| SCHEMBL23242570 | 0.90 | HTR2C (1.00) | HTR2CHTR2AHRH1 | |
| SCHEMBL10194069 | 0.89 | HTR2C (0.68) | HTR2CHTR2AHRH1HRH4 | |
| Ly2624803 SCHEMBL31208381 | 0.89 | HTR2C (0.73) | HTR2CHTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101596-B2 | Loxapine analogs and methods of use thereof | HYPNION INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101596-B2 | Loxapine analogs and methods of use thereof | HYPNION INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-7592333-B2 | Loxapine analogs and methods of use thereof | HYPNION, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592333-B2 | Loxapine analogs and methods of use thereof | HYPNION, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20090186872-A1 | LOXAPINE ANALOGS AND METHODS OF USE THEREOF | EDGAR DALE M | 2009-07-23 | — | — | US | disclosed |
| US-20090186872-A1 | LOXAPINE ANALOGS AND METHODS OF USE THEREOF | EDGAR DALE M | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186872-A1 | LOXAPINE ANALOGS AND METHODS OF USE THEREOF | HCRTR2, HCRTR1, HTR3B | HTR2C 4/4885HTR2A 9/4885HRH1 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.